Eledon Pharmaceuticals Shares Are Trading Lower After the Company Announced an $50 Million Oversubscribed Private Placement. The Company Announced Clinical Progress With Tegoprubart in the Prevention of Transplant Rejection.
Eledon Pharmaceuticals Shares Are Trading Lower After the Company Announced an $50 Million Oversubscribed Private Placement. The Company Announced Clinical Progress With Tegoprubart in the Prevention of Transplant Rejection.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.